
Oncotype DX and MammaPrint Tumor Genomic Tests: Deciding Whether Chemotherapy Is Needed
Tumor genomic tests (multigene assays) such as Oncotype DX and MammaPrint analyze gene activity in the removed cancer tissue to estimate the risk of recurrence and show whether chemotherapy would add benefit. They are used in early hormone receptor–positive, HER2-negative (HR+/HER2−) breast cancer. Large trials show that many patients do not need chemotherapy and endocrine therapy alone is enough. Namarak Hospital can send samples for both Oncotype DX and MammaPrint when indicated, using the stored surgical tissue, so no further biopsy or surgery is needed.
Why test?
Most early HR+/HER2− breast cancers are cured with surgery and endocrine therapy, and chemotherapy helps only some patients. Relying on tumor size, grade and Ki-67 alone can lead to unnecessary chemotherapy; genomic testing identifies those who truly benefit — see Understanding your pathology report
Who should be tested?
Early-stage HR+/HER2− breast cancer
Tumors larger than 0.5 cm with no lymph node involvement, or
1–3 involved lymph nodes, especially in postmenopausal women
Patients undecided about chemotherapy, when the result would change the decision
Testing is not needed for HER2-positive or triple-negative cancers, where treatment indications are already clear.
Oncotype DX (21-gene Recurrence Score)
Results are reported as a Recurrence Score (RS) from 0 to 100, interpreted according to age and lymph node status based on the TAILORx and RxPONDER trials.
No lymph node involvement (TAILORx)
RS 0–25 in women over 50 — endocrine therapy alone, no chemotherapy
RS 0–15 in women aged 50 or younger — endocrine therapy alone
RS 16–25 in women aged 50 or younger — a small benefit from chemotherapy is possible, or ovarian suppression with endocrine therapy may be considered instead
RS 26–100 — chemotherapy plus endocrine therapy is recommended
1–3 involved lymph nodes (RxPONDER)
Postmenopausal and RS 0–25 — endocrine therapy alone, no chemotherapy
Premenopausal — chemotherapy still provides benefit even with a low RS, partly through ovarian suppression; discuss ovarian suppression options with your doctor
RS 26 or higher — chemotherapy is recommended
MammaPrint (70-gene signature)
Results are reported as low risk or high risk
The MINDACT trial showed that patients at high clinical risk but low MammaPrint risk, especially those over 50, can safely omit chemotherapy with almost no difference in outcome
Can be used for node-negative and 1–3 node-positive disease
Process and practical points
Uses tissue already stored in paraffin blocks from surgery or biopsy, sent to an overseas laboratory — no extra biopsy needed
Results take about 2–3 weeks, which does not delay treatment enough to cause harm
The cost is relatively high and insurance coverage varies; our team will explain costs before sending the test
It is not an inherited gene test — it examines the tumor’s genes and does not show family risk, which requires a separate blood test; see Multigene panel genetic testing
Frequently asked questions (FAQ)
How does Oncotype DX differ from BRCA testing?
Oncotype DX tests genes in the tumor to guide chemotherapy decisions, while BRCA testing examines inherited genes in blood or saliva to assess family risk. They are different tests.
Does a low Recurrence Score mean no chemotherapy?
For women over 50 without lymph node involvement, a score of 0–25 means chemotherapy is not needed. For younger women or those with positive nodes, interpretation differs and your doctor will consider other factors.
Who does not need the test?
Patients with HER2-positive or triple-negative cancer, where treatment indications are clear, and those for whom the result would not change the decision, such as very small low-risk tumors or many involved lymph nodes.
Do I need another biopsy for the test?
No. The test uses tissue already stored from your surgery or previous biopsy.
How do doctors choose between Oncotype DX and MammaPrint?
Both are supported by evidence in international guidelines. Oncotype DX indicates both risk and chemotherapy benefit, while MammaPrint classifies risk as low or high. Your doctor will choose based on your situation.
About Namarak Hospital
Namarak Hospital is a specialized breast and breast cancer hospital in Bangkok, providing complete care in one place — from diagnosis with 3D mammography, ultrasound, automated breast ultrasound (ABUS) and biopsy to comprehensive breast cancer treatment, including breast-conserving and reconstructive surgery, intraoperative radiotherapy (IORT), chemotherapy, targeted therapy and endocrine therapy, planned by a multidisciplinary team according to the latest international guidelines. See Breast cancer treatment: a complete guide, contact us on LINE, tel. +66 2 059 0245, or our Second Opinion service.
Related articles
References
Sparano JA, et al. Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer (TAILORx). N Engl J Med 2018;379:111–21
Kalinsky K, et al. 21-Gene Assay to Inform Chemotherapy Benefit in Node-Positive Breast Cancer (RxPONDER). N Engl J Med 2021;385:2336–47
Cardoso F, et al. 70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer (MINDACT). N Engl J Med 2016;375:717–29
Andre F, et al. Biomarkers for Adjuvant Endocrine and Chemotherapy in Early-Stage Breast Cancer: ASCO Guideline Update. J Clin Oncol 2022;40:1816–37
NCCN Clinical Practice Guidelines in Oncology: Breast Cancer, Version 4.2026
Medically reviewed by: Namarak Hospital medical team · Last checked: 17 November 2026 · This information is for general education and is not individual medical advice. Please consult your doctor for diagnosis and treatment suited to you.





Comments